Stephen Ansell, MD, PhD, professor of medicine at the Mayo Clinic in Minnesota, explains the 2 main types of patients with Waldenström Macroglobulinemia (WM), a rare type of slow-growing, non-Hodgkin lymphoma.
Some types of WM present with very few symptoms and are generally only detected because the monoclonal immunoglobulin M antibody, or macroglobulin, protein that is overproduced in WM is detected. This type is generally referred to as indolent WM and may not require therapy, these patients are generally monitored without being treated and will not require treatment for many years.
Patients with WM that present symptoms, which includes weakness, swollen lymph nodes, severe fatigue, nose bleeds, weight loss, and visual and neurological problems, require treatment. Treatment will begin with plasmapheresis followed by chemotherapy plus rituximab.
An improved assay for assessing MRD status in patients with multiple myeloma is contributing to the momentum for using MRD as a surrogate endpoint for survival in clinical trials and as a tool with the potential to help guide therapy choices.
Five early-phase clinical trials exploring chimeric antigen receptor (CAR) T-cell therapy have been suspended temporarily in response to the deaths of 2 patients with adult B-cell acute lymphoblastic leukemia